Abstract:
A method and apparatus for reducing or inactivating pathogens in units of whole blood. A plurality of superparamagnetic nanoparticles (SPN) is coated with a mixture of chemiluminescence light-generating compounds and photodynamic broad-spectrum anti-viral compounds, and the mixture in introduced into a bag of whole blood. A rapidly-changing electromagnetic field is applied to the bag to cause uniform distribution of the nanoparticles within the whole blood throughout all regions of the blood bag, including the opaque interior of the bag. The blood is processed for a predetermined processing time period, during which the chemiluminescence light activates the broad-spectrum antiviral capacity of the photodynamic compounds to achieve reduction or inactivation of pathogens throughout the blood bag. After the processing time is elapsed, the nanoparticles are removed from the processed blood by a magnetic field. The processed blood may be washed by conventional means, to remove residual reagents, and transferred into a new, sterile blood bag.
Abstract:
This invention is for improving the manufacturing pharmaceutical grade CBD and other cannabinoids following current Good Manufacturing Practices (cGMP) of the US FDA for use in clinical trials for CNS and other indications by the NIH and other researchers. The major cannabinoids in marijuana (Cannabis) and hemp originate from Cannabigerolic Acid (CBGA) present in the biomass of the plant. Plant enzymes that are specific to different strains of biomass converts CBGA to different carboxylic acids of cannabinoids including Cannabidiolic Acid (CBDA) and Δ9-Tetrahydrocannabinolic Acid (Δ9-THCA). These are relatively stable in the growing and fresh-cut plants. These are converted by thermal decarboxylation to Cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC), carbon dioxide and water. Cannabinoids can be manufactured by first heating the Cannabis biomass to convert carboxylic acids prior to extraction and purification. Alternatively, and preferably because of manufacturing cost and product stability, the carboxylic acids can be first extracted and purified. They can be utilized in the carboxylic acid form or stored in a stable manner until converted to cannabinoids for use in medicine. This invention provides an efficient method for their conversion utilizing a high-pressure reactor under inert conditions.
Abstract:
The present invention is directed to methods, kits and compositions for inactivating viral agents in or on articles including blood-based products and feature a light sensitive compound selected from the group consisting of hypericin, pseudohypericin and hypocrellin, a group of light producing compounds comprising luciferase, luciferin, ATP and CDP Star, and emission enhancers or quenchers selected from the group consisting of as Sapphire, Emerald, Ruby, Sapphire-II and Emerald-II.
Abstract:
This invention is for an improved process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid liposomes. Non-toxic supercritical or near-critical fluids with/without polar cosolvents are utilized to solubilize phospholipid materials and hydrophobic drugs, and form uniform liposomes to encapsulate hydrophobic drugs and hydrophilic drugs.
Abstract:
St. John's Wort products which have enhanced bioactivity in a serotonin re-uptake assay and enhanced stability are identified and manufactured from Hypericum perforatum biomass with supercritical and near critical fluids with and without polar cosolvents. These fluids are used to fractionate the biomass materials in several sequential steps. In each step, the biomass is subjected to a multiplicity of supercritical or near critical fluid extraction steps, with different solvation conditions used for each fraction. Thus, fractionation of the biomass is effected and the St. John's Wort products are manufactured. In addition to excellent overall yield, the bioactivity and stability of the St. John's Wort products manufactured from Hypericum perforatum biomass with supercritical and near critical fluids with and without polar cosolvents are significantly higher than that obtained by conventional organic phase extraction.
Abstract:
The present invention is for a continuous-flow pathogen reduction apparatus and method, based purely on pathogen inactivation physical principles, for controlling or eliminating trans fusion-transmittable infections from emerging pathogens, pandemic viruses, and bioterrorism threats. The invention inactivates both nonenveloped and enveloped viruses as well as pathogenic bacteria and parasites in human plasma and biologies, while retaining the natural bioactivity, integrity and potency of the treated biologic. The method uses critic al, near-critical or supercritical fluids for viral and pathogen reduction of plasma and biologies. The apparatus is designed to rapidly process high volumes of plasma and biologies with high levels of pathogen reduction in a continuous flow fashion.
Abstract:
This invention is for improved extracting, separating, and manufacturing pharmaceutical grade CBD and other cannabinoids following current Good Manufacturing Practices (cGMP) of the US FDA for use in clinical trials for central nervous system (CNS) and peripheral nervous system (PNS) disorders such as pain, opioid use disorder, anxiety, epilepsy, nausea and vomiting, Multiple sclerosis and other indications by the National Institute of Health (NIH) and other researchers. This invention first established optimum conditions for the selective SuperFluids™ [supercritical fluids and near-critical fluids with or without polar co-solvents such as alcohols] fractionation of Cannabis sativa to isolate CBD, CBDA, Δ9-THC, Δ9-THCA and other cannabinoids Δ9-THC; then defined SuperFluids™ chromatographic purification conditions for the further purification of CBD, CBDA, Δ9-THC, Δ9-THCA with absolute purities >98.5%. This invention is for methods and apparatus to manufacture pharmaceutical-grade CBD and CBDA (98.5% to 100% with
Abstract:
This invention relates to a composition of matter using enhanced gingerols for treating nausea and emesis associated with cancer chemotherapy, pregnancy, elective surgery, radiation therapy, motion sickness, and drug medications, use and schedule of use as well as methods of making. A method of making the enhanced gingerols features supercritical, critical and near-critical fluids with and without polar cosolvents. The capsules include an enhanced extract of ginger rhizome wherein said ginger rhizome has a starting mass and said extract has a 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol mass and said ratio of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol mass to starting mass is 90-100%.
Abstract:
This invention relates to methods and systems for removing plaque from arteries and blood vessels in human subjects non-invasively utilizing coated superparamagnetic nanoparticles introduced into the human bloodstream and controlled by external magnetic fields to effect plaque removal. Magnetic nanoparticles are injected into a patient, and magnetic fields are used to move the nanoparticles to the site of an arterial blockage. The nanoparticles are then oscillated by means of an alternating current source and oscillating magnetic field. The nanoparticles impact the plaque deposit, causing it to break up, so that it may be safely disintegrated, dissolved in the bloodstream, digested by enzymes or ions and/or removed with the nanoparticles themselves. The nanoparticles are removed by a unipolar magnetic field directing them to be removed at the point of injection or alternative location in the body. The nanoparticles are also removed by natural bodily functions. The methods and systems are directed to the emergency clearance of arteries in the human body, and the routine annual and quarterly clearance and preventative maintenance of arteries in the human body.